#1 Clinical Trials Search in Europe

Cefepime

Cefepime is a fourth-generation cephalosporin antibiotic that has been the subject of several clinical trials to evaluate its effectiveness and safety in treating various infections. This article explores the use of cefepime in clinical studies, focusing on its application in urinary tract infections, pneumonia, and other bacterial infections. We’ll examine different administration methods, dosing regimens, and comparisons with other antibiotics to provide a comprehensive overview of cefepime’s role in modern medicine.

Table of Contents

What is Cefepime?

Cefepime is a powerful antibiotic medication that belongs to a class of drugs called beta-lactam antibiotics. It’s also known by its brand name Maxipime[3]. Cefepime is used to treat various bacterial infections and is particularly effective against a wide range of bacteria, including some that may be resistant to other antibiotics.

What Conditions Does Cefepime Treat?

Cefepime is used to treat several types of infections, including:

  • Urinary Tract Infections (UTIs): Including complicated UTIs and kidney infections (pyelonephritis)[5]
  • Respiratory Tract Infections: Such as pneumonia, including hospital-acquired and ventilator-associated pneumonia[4][10]
  • Septic Shock: A severe condition where infection leads to dangerously low blood pressure[1]
  • Febrile Neutropenia: A condition in cancer patients where fever occurs along with a low white blood cell count[3]

How is Cefepime Administered?

Cefepime is typically given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The dosage and duration of treatment can vary depending on the type and severity of the infection, as well as other factors like kidney function. Some common administration methods include:

  • Standard Infusion: Given over 30 minutes every 8 or 12 hours[3]
  • Extended Infusion: Given over 3 or 4 hours, which may be more effective for certain infections[1][4]
  • Continuous Infusion: Given continuously over 24 hours[2]

In some cases, cefepime may also be given as an intramuscular (IM) injection, which means it’s injected into a muscle[6].

Effectiveness of Cefepime

Research has shown that cefepime is effective in treating various bacterial infections. Some key points about its effectiveness include:

  • It’s often compared to other antibiotics like meropenem, piperacillin-tazobactam, and ceftriaxone in clinical trials[1][10][6]
  • Extended or continuous infusions of cefepime may be more effective than standard infusions for certain infections[2][4]
  • It’s being studied in combination with other drugs like AAI101 and taniborbactam to potentially improve its effectiveness against resistant bacteria[9][8]

Cefepime in Special Populations

Cefepime’s use and dosing may need to be adjusted for certain groups of people:

  • Patients with Kidney Problems: The dosage of cefepime may need to be adjusted for people with reduced kidney function or those on dialysis[7]
  • Elderly Patients: Older adults, particularly those in nursing homes, may be prescribed cefepime for infections like pneumonia[6]
  • Cancer Patients: Cefepime is often used to treat febrile neutropenia in cancer patients undergoing chemotherapy[3]

Ongoing Research and Future Developments

Researchers are continuously studying cefepime to improve its effectiveness and expand its uses. Some areas of ongoing research include:

  • Combination Therapies: Cefepime is being studied in combination with other drugs like AAI101 and taniborbactam to potentially improve its effectiveness against resistant bacteria[9][8]
  • Optimizing Dosing Regimens: Studies are looking at different ways of administering cefepime, such as extended or continuous infusions, to maximize its effectiveness[4]
  • Use in Specific Conditions: Researchers are investigating cefepime’s effectiveness in treating specific types of infections, such as ventilator-associated pneumonia[10]
Aspect Details
Primary Indications Complicated urinary tract infections (cUTIs), pneumonia (including VAP and HAP), sepsis with bacteremia
Administration Methods Intravenous (IV) infusion: standard (30 minutes), prolonged (3-4 hours), continuous (24 hours)
Dosing Regimens Varies by study: 1-2g every 8 hours, with adjustments for renal function
Comparator Drugs Meropenem, ceftriaxone, flomoxef
Special Populations Studies in patients with renal impairment, critically ill patients
Combination Therapies Cefepime-taniborbactam, cefepime-AAI101 for resistant infections
Key Outcomes Measured Clinical cure, microbiological eradication, mortality rates, adverse events
Safety Considerations Monitoring for adverse events, dose adjustments in renal impairment

FAQ

  • What is cefepime and what is it used for? Cefepime is a fourth-generation cephalosporin antibiotic. It is used to treat various bacterial infections, including urinary tract infections, pneumonia, and other serious infections caused by susceptible bacteria.
  • How is cefepime administered in clinical trials? In clinical trials, cefepime is typically administered intravenously (IV). Different studies have explored various administration methods, including standard infusions lasting 30 minutes, prolonged infusions lasting 3-4 hours, and continuous infusions over 24 hours.
  • What are some common comparator drugs used in cefepime clinical trials? Common comparator drugs in cefepime clinical trials include other antibiotics such as meropenem, ceftriaxone, and flomoxef. These comparisons help evaluate cefepime's efficacy relative to established treatments.
  • What types of infections are being studied in cefepime clinical trials? Cefepime clinical trials have focused on various infections, including complicated urinary tract infections (cUTIs), pneumonia (including ventilator-associated and hospital-acquired pneumonia), and sepsis with bacteremia.
  • Are there any special considerations for cefepime use in patients with renal impairment? Yes, several studies have investigated cefepime's pharmacokinetics in patients with varying degrees of renal function. Dose adjustments may be necessary for patients with renal impairment to ensure safe and effective treatment.

Ongoing Clinical Trials on Cefepime

  • Study on the Effectiveness of Moxifloxacin and Drug Combination for Treating Bone Implant Infections in Patients with Long Bone Fractures

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on the Effectiveness and Safety of 7 vs. 14 Days of Antibiotic Treatment with Meropenem for Patients with Pseudomonas Aeruginosa Blood Infection

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Early Stopping of Antibiotic Treatment in Children with Cancer and Febrile Neutropenia

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Impact of Cefepime, Piperacillin-Tazobactam, and Ceftobiprole on Gut Health in Patients with Bone and Joint Infections on Implants

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Cefepime and Enmetazobactam for Children with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Hungary Poland Slovakia Spain

  • Study Comparing Different Antibiotic Treatments for ICU Patients with Hospital-Acquired Sepsis: Focus on Cefepime and Drug Combination

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Antibiotic Monitoring in ICU Patients Using Meropenem and Drug Combination

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Resistant Bacterial Infections

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Croatia Czechia France Greece Latvia Slovakia +1

  • Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Bulgaria Czechia Estonia Latvia Lithuania Slovakia

  • Study on Cefepime for Patients with Chronic Kidney Disease on Peritoneal Dialysis Without Peritonitis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

Glossary

  • Cefepime: A fourth-generation cephalosporin antibiotic used to treat various bacterial infections.
  • Complicated Urinary Tract Infection (cUTI): A urinary tract infection that is associated with structural or functional abnormalities of the genitourinary tract or the presence of an underlying disease that interferes with host defense mechanisms.
  • Ventilator-Associated Pneumonia (VAP): A type of pneumonia that develops in patients who are on mechanical ventilation for more than 48 hours.
  • Hospital-Acquired Pneumonia (HAP): Pneumonia that develops 48 hours or more after hospital admission and was not incubating at the time of admission.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Infusion: The slow introduction of a solution into a vein or other tissue.
  • Bacteremia: The presence of bacteria in the bloodstream.
  • Sepsis: A life-threatening condition that arises when the body's response to infection causes widespread inflammation and organ dysfunction.
  • Renal Impairment: A condition where the kidneys are not functioning properly, which can affect drug metabolism and excretion.
  • Microbiological Eradication: The elimination of disease-causing microorganisms from a patient's body as a result of treatment.

References

  1. https://clinicaltrials.gov/study/NCT02820987
  2. https://clinicaltrials.gov/study/NCT00609375
  3. https://clinicaltrials.gov/study/NCT01484015
  4. https://clinicaltrials.gov/study/NCT02568800
  5. https://clinicaltrials.gov/study/NCT02302092
  6. https://clinicaltrials.gov/study/NCT00358202
  7. https://clinicaltrials.gov/study/NCT03680352
  8. https://clinicaltrials.gov/study/NCT04951505
  9. https://clinicaltrials.gov/study/NCT03680612
  10. https://clinicaltrials.gov/study/NCT06168734